Skip to content

US · TARS · BIOTECHNOLOGY

Tarsus Pharmaceuticals, Inc. (TARS) intrinsic value and stock valuation

$73.01as of 2026-11-21 · Mkt cap 2.64B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Tarsus Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values TARS with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from TARS’s statements →

Tarsus Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Irvine, CA 92618 tarsusrx.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$451.4M
20182025
Net income
-$-66.42M
20182025
Free cash flow
-$-22.31M
20182025
Total equity
$343.4M+15.7% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$451.4M$183M$17.5M$25.8M$57M
Operating income-$-70.97M-$-120.57M-$-143.16M-$-62.71M-$-12.16M
Net income-$-66.42M-$-115.55M-$-135.89M-$-62.09M-$-13.83M
EPSd-$-1.59M-$-3.07M-$-4.63M-$-2.52M-$-672.99K
Operating cash flow-$-12.45M-$-83.03M-$-117.49M-$-49.03M$3.75M
Capital expenditure-$-9.86M-$-1.57M-$-5.5M-$-510K-$-590K
Free cash flow-$-22.31M-$-84.59M-$-123M-$-49.54M$3.16M
Total assets$562.2M$377M$265.5M$227.9M$178.9M
Total debt$93.6M$72.5M$30.2M$20.2M$1.89M
Net debt-$-90M-$-22.37M-$-194.73M-$-51.45M-$-169.44M
Total equity$343.4M$224.5M$197M$192.9M$166.7M
Cash and short-term investments$417.3M$291.4M$227.4M$217M$171.8M
Income statement
20252024202320222021
Revenue$451.4M$183M$17.5M$25.8M$57M
Cost of revenue$30.7M$12.8M$1.59M$950K$2.08M
Gross profit$420.7M$170.1M$15.9M$24.9M$55M
Research and development expenses$64.3M$53.4M$50.3M$42.6M$41.7M
Selling, general and administrative expenses$427.3M$237.3M$108.7M$45M$25.4M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$491.6M$290.7M$159M$87.6M$67.1M
Cost and expenses$522.3M$303.5M$160.6M$88.5M$69.2M
Interest income$15.8M$15M$10.3M$3.5M$40K
Interest expense$8.94M$7.45M$3.23M$2.06M$0.00
Depreciation and amortization$1.82M$1.23M$880K$330K$310K
Ebitda-$-53.61M-$-106.48M-$-131.67M-$-59.7M-$-13.46M
Operating income-$-70.97M-$-120.57M-$-143.16M-$-62.71M-$-12.16M
Total other income/expenses, net$6.61M$5.01M$7.26M$620K-$-1.61M
Income before tax-$-64.36M-$-115.55M-$-135.89M-$-62.09M-$-13.77M
Income tax expense$2.06M$0.00$0.00-$0.00$60K
Net income-$-66.42M-$-115.55M-$-135.89M-$-62.09M-$-13.83M
Weighted average shares outstanding$41.8M$37.6M$29.4M$24.6M$20.6M
Weighted average diluted shares outstanding$41.8M$37.6M$29.4M$24.6M$20.6M
Balance sheet
20252024202320222021
Cash and short-term investments$417.3M$291.4M$227.4M$217M$171.8M
Net receivables$87.1M$48.1M$17.7M$3.58M$90K
Inventory$4.37M$2.62M$3.11M$0.00$0.00
Total current assets$522.8M$356.7M$256.1M$225.4M$176M
Property, plant and equipment, net$21.8M$2.87M$3.35M$1.53M$1.83M
Goodwill and intangible assets$7.37M$8.33M$3.87M$0.00$0.00
Long-term investments$3.87M$3M$630K$370K$660K
Total non-current assets$39.4M$20.3M$9.36M$2.49M$2.96M
Total assets$562.2M$377M$265.5M$227.9M$178.9M
Accounts payable$16.4M$27.7M$17.8M$5.5M$2.86M
Short-term debt$0.00$610K$400K$720K$1.31M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$135.7M$80.6M$36.9M$15.4M$11.5M
Long-term debt$93.6M$71.8M$29.8M$19.5M$580K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$83M$71.8M$31.6M$19.5M$700K
Capital lease obligations$10.6M$610K$400K$770K$1.89M
Total liabilities$218.7M$152.5M$68.5M$35M$12.2M
Common stock$10K$10K$10K$10K$0.00
Retained earnings-$-426.63M-$-360.21M-$-244.66M-$-108.76M-$-46.67M
Accumulated other comprehensive income (loss)$380K$180K-$0.00-$-70K$0.00
Total equity$343.4M$224.5M$197M$192.9M$166.7M
Total investments$237.5M$199.6M$3.13M$145.7M$1.15M
Total debt$93.6M$72.5M$30.2M$20.2M$1.89M
Net debt-$-90M-$-22.37M-$-194.73M-$-51.45M-$-169.44M
Cash flow statement
20252024202320222021
Net income-$-66.42M-$-115.55M-$-135.89M-$-62.09M-$-13.83M
Depreciation and amortization$1.82M$1.23M$880K$330K$310K
Stock-based compensation$41.7M$27.8M$19.8M$13.5M$8.46M
Change in working capital$14.6M$3.84M$310K-$-950K$1.37M
Accounts receivable-$-39.05M-$-30.14M-$-14.13M-$-3.49M-$-70K
Inventory-$-1.75M-$-2.05M-$-3.11M$3.49M$0.00
Accounts payable$6.91M$40.3M$13.2M$820K$3.88M
Net cash provided by operating activities-$-12.45M-$-83.03M-$-117.49M-$-49.03M$3.75M
Investments in property, plant and equipment-$-9.86M-$-1.57M-$-1.5M-$-510K-$-590K
Acquisitions, net$0.00$0.00$0.00$144.1M$0.00
Net cash used for investing activities-$-42.12M-$-199.19M$140.6M-$-144.63M-$-590K
Common stock issued$143.4M$115.1M$120.2M$74.9M$20K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$143.4M$154.7M$130.2M$94M$20K
Net change in cash$88.8M-$-127.57M$153.3M-$-99.67M$3.18M
Cash at end of period$186.2M$97.4M$225M$71.7M$171.3M
Operating cash flow-$-12.45M-$-83.03M-$-117.49M-$-49.03M$3.75M
Capital expenditure-$-9.86M-$-1.57M-$-5.5M-$-510K-$-590K
Free cash flow-$-22.31M-$-84.59M-$-123M-$-49.54M$3.16M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Tarsus Pharmaceuticals, Inc.

        Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.

        CEO
        Bobak R. Azamian
        Employees
        370
        Beta
        0.50

        Explore

        Frequently asked questions

        What is the intrinsic value of Tarsus Pharmaceuticals, Inc. (TARS)?

        Tarsus Pharmaceuticals, Inc. (TARS) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is TARS undervalued?

        TARS trades at a price of $73.01 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.